Prospect

Now enrolling. A Randomized, Double-Blind, Phase 3 Efficacy Trial of
PROSTVAC-V/F ± GM-CSF in Men with Asymptomatic or Minimally
Symptomatic Metastatic, Castrate-Resistant Prostate Cancer (mCRPC).